期刊文献+

降钙素原及乳酸水平在脓毒血症中的临床意义 被引量:3

在线阅读 下载PDF
导出
摘要 目的检测脓毒血症患者血降钙素原(procalcitonin,PCT)和血乳酸含量的变化,探讨其在脓毒血症中的临床意义。方法收集2013年1月—2014年6月该院85例脓毒血症患者的临床资料,将其按病情严重程度分为早期脓毒血症组严重脓毒血症组和脓毒症休克组,并按临床治疗终点分为存活组和死亡组,监测不同程度脓毒症患者血清中PCT和乳酸水平变化及存活组与死亡组患者血清中PCT和乳酸水平。结果严重程度不同的脓毒血症患者血清PCT及乳酸水平差异有统计学意义,P<0.05;死亡组的PCT及乳酸水平明显高于存活组,P<0.05。结论血清降钙素原及乳酸水平测定对脓毒血症患者病情严重程度与预后判断具有指导意义。
出处 《中外医疗》 2015年第3期177-178,共2页 China & Foreign Medical Treatment
基金 深圳市科技计划项目 实时荧光PCR在急诊严重脓毒症患者病原学快速诊断中的价值研究课题(201302021)
  • 相关文献

参考文献10

  • 1Peake SL, Bailey M, Bellomo R, et al.Australasian resuscitation of sepsis evaluation (ARISE):A multicentre prospective,inception cohort study[J].Resuscitation, 2009, 80(7) : 811-818.
  • 2Rey C, Los A M, Concha A, et al. Procalcitonin and C -reactive protein as markers of systemic inflammatory response syndrome severity in criti- cally ill children[J].Intensive Care Med, 2007,33(3):477-484.
  • 3Karlsson S,Heikkinen M,Pettila V,et al.Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study[J]. Crit Care,2010,14(6) :R205.
  • 4蒋迎佳,谢成,罗红权,施红,马涛,刘海婷,刘艳梅.危重患儿血清降钙素原与全身炎症反应综合征的相关性研究[J].中国妇幼保健,2010,25(21):2973-2975. 被引量:12
  • 5Nobre V,Harbarth S, Graf J D,et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized triM[J]. Am J Respir Crit Care Med,2007,177(5) :498 -505.
  • 6蒋贤高,汪晓波,王仁数.脓毒血症患者监测血清降钙素原、C反应蛋白的临床意义[J].中国呼吸与危重监护杂志,2009,8(5):429-431. 被引量:63
  • 7Nguyen HB,Rivers EP,Knoblich BP,et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock[J]. Crlt Care Med, 2004, 32(8) :1637-1642.
  • 8贺丽,杨超,张文田,金晓烨,赵晓.血乳酸水平与重症监护病房危重患者预后的关系[J].中华全科医学,2012,10(5):731-732. 被引量:12
  • 9Singhal R,CoghillJE,Guy A,et al.Serum lactate and basedeficit as predictors of mortality after ruptured abdominal aorticaneurysmrepair [J]. Eur J Vasc Endovasc Surg, 2005,30(3) : 263-266.
  • 10王明达,邹文武.血清乳酸监测对判断危重病人预后的价值[J].医学临床研究,2011,28(12):2316-2318. 被引量:15

二级参考文献35

  • 1葛庆岗,阴赪宏,文艳,吕旌乔,王谊冰.血清降钙素原与多器官功能障碍综合征严重程度相关性的临床研究[J].中国危重病急救医学,2005,17(12):729-731. 被引量:28
  • 2陈海雁.急性危重病患者血乳酸(LACT)与血气检测的临床应用[J].临床和实验医学杂志,2007,6(7):91-91. 被引量:34
  • 3Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS international sepsis definitions conference. Crit Care Med, 2003,31:1250-1256.
  • 4Vincent JL, Moreno R,Takala J, et al. The SOFA score to describe organ dysfunction/failure. Intensive Care Med, 1996,22:707-710.
  • 5Guven H, Altintop L, Baydin A, et al. Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am J Emerg Med ,2002,20:202-206.
  • 6Balci C,Sungurtekin H, Gurses E, et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care ,2003,7 : 85 -90.
  • 7Yukioka H, Yoshida G, Kurita S. Plasma procalcitonin in sepsis and organ failure. Ann Acad Med Singapore ,2001,30,528-531.
  • 8Luzzani A, Polati E, Dorizzi R, et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med, 2003, 31 : 1737-1741.
  • 9彭文伟,主编.传染病学.第6版,北京:人民卫生出版社,2005,67-68.
  • 10Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin concentrations correlate with survival in patients with the sepsis syndrome [J] .AnnIntern Med, 1993, 119:771.

共引文献96

同被引文献42

  • 1刘晓蓉,任新生.脓毒症凝血机制及组织因子通路抑制剂治疗的研究现状及治疗进展[J].中国急救医学,2005,25(11):833-835. 被引量:19
  • 2魏芳,王立华,姜埃利.脓毒血症与内皮细胞功能异常[J].国际移植与血液净化杂志,2006,4(5):9-12. 被引量:2
  • 3吴健,李澎,陈卫民.血清C反应蛋白水平预测危重症患者预后的临床研究[J].中国医科大学学报,2007,36(3):358-358. 被引量:11
  • 4吴盂超,吴在德.黄家驷外科学[M].7版.北京:人民卫生出版社,2008:1768-1777.
  • 5Galley H F. Oxidative stress and mitochondrial dusfunc- tion in sepsis [J]. BrJ Anaesh, 2011, 107 (1): 57.
  • 6Bone RC, Balk RA, Cerra FB, et al. Definitions for sep- sis and organfailure and guidelines for the use of innovative therapies in sepsis. TheACCP/SCCM Consensus Confer- ence Committee. American Collegeof Chest Physicians/So- ciety of Critical Care Medicine [J]. Chest, 1992, 101 (6) : 1644 - 1655.
  • 7RLSSL, LL, J A. Management of sepsis [J]. N EnglJ Med, 2006, 355 (16) : 1699 - 1713.
  • 8Spek CA, Koster T, Rosendaal F R, et al. Genotypic variation in the promotor region of the protein C gene is as- sociatedwith plasma protein C levels and thrombotic risk [ J ]. Arterioscler Thromb Vasc Biol, 1995, 15 ( 2 ) : 214 -218.
  • 9Heizmann CW, Ackermann GE, Galichet A. Pathologies involving the S100 protein and RAGE [ J]. Subcell Bio- chem, 2007, 45: 93-158.
  • 10Mori Y, Kosaki A, Kishimoto N, et al. Increased plas- ma S100A12 (EN- RAGE) levels in hemodialysis pa- tients with atherosclerosis [ J]. Am J Nephrol, 2009, 29 (1): 18-24.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部